Immunological tolerance to a soluble, partially purified fraction of histocompatibility (H)-2a antigen was induced in B1O.D2 strain mice. The fraction used was obtained after chromatography on a Sephadex G-150 column. Tolerance of humoral-antibody formation (cytotoxins and hemagglutinins) was observed in mice injected with soluble antigen since birth, but cell-mediated immunity, as measured by skin graft survival, remained intact. Tolerance was shown to be specific for H-2a antigens, since treated mice produced a regular humoralantibody response to H-2b antigens. These findings, along with previous observations of the immunogenic and enhancing properties of our partially purified fraction, suggest that the solubilized antigen contains all the major determinants of H-2a antigens expressed on lymphoid-cell surfaces.
The major histocompatibility antigens in mice are molecules bound to cell membranes and controlled by the histocompatibility-2 (H-2) gene(s) (1) (2) (3) . We have previously solubilized and partially purified H-2 antigens from spleen cells of A/J mice (4, 5) , using a modification of the papain digestion procedure of Nathenson and Shimada (6) . These solubilized antigens are able to evoke immunity to skin allografts in congenic strains differing only at the H-2 locus (4, 5) , and to produce specific enhancement of tumor allograft survival in noncongenic strains (7) . These findings show that H-2 antigens solubilized with papain are not only immunogenic, but also contain all the important determinants that are involved in the evocation of transplantation immunity.
The present studies were designed to test the ability of partially purified, soluble H-25 antigens derived from A/J mice to induce immunological tolerance of both cell-mediated and humoral immunity in B1O.D2 mice. The tolerizing regimen was similar to that described by Mitchison (8) and Nossal et al. (9) to produce specific immunological paralysis to bovine serum albumin and Salmonella adelaide flagellin, respectively, in mice. The induction of tolerance with H-2 antigens solubilized with papain provided further evidence that papain digestion releases materials from lymphoid-cell membranes that contain all the important H-2 determinants present on the in situ molecule. In addition, tests for tolerogenicity, as well as tests for immunogenicity and enhancement, confirm that the integrity of the multiple biological functions of the H-2 molecules have been preserved.
Abbreviation: H, histocompatibility.
MATERIALS AND METHODS
Antigenic Materials. Preparation of the crude membrane material and treatment with papain were performed as described (4, 5) . Batches of 1000 spleens from A/J mice were used routinely as a starting material. The papain-solubilized material, after concentration by ultrafiltration, was chromatographed on a Sephadex G-150 column (2.5 X 160 cm) at 4°. H-2 alloantigenic specificities, measured by a modification of the in vitro (51Cr release) cytotoxic inhibition assay (10), were confined to fraction (F2), which was in the included volume. Material pooled from this fraction, with a specific activity comparable to that reported previously for H-2.1,3 and H-2.1 1, was used throughout this study (4, 5) . Antisera directed against H-2 specificities used in the cytotoxic inhibition assay were obtained from the Jackson Laboratory through NIAID, Bethesda Hemagglutinins of the several groups of sera obtained from B1O.D2 mice were assayed by the method of Stimpfling (12) .
Absorptions of individual sera were performed with 1 volume of packed A/J spleen cells and 2 volumes of undiluted serum. Two consecutive absorptions for 30-min periods at room temperature were used. Skin Grafting. B1O.A full-thickness skin grafts, about 15 mm in diameter, from 4-week-old female donors were placed mid-dorsally and anchored with stainless-steel wound clips. The clips were removed after 7 days and skin rejection was assessed by gross inspection. An attempt was made to assess the beginning of the breakdown of the graft. The more objective measure of graft rejection, however, was complete rejection, i.e., sloughing of the graft.
Syngeneic grafts of B1O.A skin grafts to B1O.A (4 grafts) and of B1O.D2 to B1O.D2 (4 grafts) have persisted for more than 100 days.
Tests for Enhancing Antibody. Sera from antigen-treated and control mice were tested for their ability to passively enhance the growth of tumor allografts (13, 14) . In these experiments, B1O.D2 male recipients, 12 weeks of age, were injected intraperitoneally with 0.2 ml of a 1/10 dilution of each serum to be assayed for enhancing antibody, and within 60 min, were inoculated subcutaneously with 107 Sarcoma I (SaI; H-2a) cells. Tumors were measured twice weekly and scored as positive if they were at least 4 mm in their greatest diameter.
RESULTS
The results of the skin grafting experiment after 4 In contrast to the findings of skin graft rejection, B1O.D2 mice treated with H-2a antigen showed a marked depression of humoral-antibody formation. Cytotoxic and hemagglutinating antibody titer, measured at 4 weeks after skin grafting, were moderate in control mice, whereas antibody titers were undetectable in mice treated with antigen (Fig. 2) .
Antibody responses in these two groups were measured again at 11 and 21 days after intraperitoneal inoculation of 40 X 106 B1O.A spleen cells (Fig. 1) . Again the titer of cytotoxins and hemagglutinins in the group injected from birth with solubilized H-21 antigen was strikingly lower than in the control group (Fig. 2) .
The possibility existed that unresponsiveness among the mice treated with antigen to B1O.A skin grafts and spleen cells resulted from nonspecific suppression of the immune response. Nonspecific suppression has been recorded after immunization with soluble protein antigens (15). To test the specificity of this unresponsiveness, both groups of mice received intraperitoneal injections of 40 and 60 X 106 B10 (H-2b) spleen cells, and the resultant antibody responses were measured by use of B10 target cells (Fig. 1) body titers measured 10 days after the second injection of cells were not significantly different in the two groups (Fig.  3) .
In further experiments, these sera were assayed for antibodies against H-2a specificities and against unshared H-2b specificities. In the assay for antibodies against H-2a specificities, antisera were titered against B10.A (H-2a) target cells, and in the assay against unshared H-2b specificities, antisera were first absorbed with B10.A cells and then titered against B10 (H-2a) target cells. Table 2 shows that cytotoxic antibody titers directed against H-2b specificities were about 64-times higher in control mice than in mice injected with antigen. On the other hand, cytotoxic antibody titers against unshared H-2b specificities were almost identical ( Table 2) .
Measurement of enhancement of antibodies in a small number of mice was done to provide additional evidence of unresponsiveness to humoral antibody production in mice treated with antigen. The results shown in Table 3 (14) . We have recently shown that a H-2a antigen solubilized with papain and partially purified by gel filtration on a Sephadex G-150 column is able to specifically elicit sensitization to skin allografts in congenic mice differing only at the H-2 locus (4, 5) and to elicit enhancement of tumor allografts in noncongenic strains differing at both H-2 and non-H-2 loci (7).
In the present study, we tested the ability of the same partially purified material derived from the spleen cells of A/J mice to elicit tolerance for both cell-mediated and humoral immunity in B10.D2 mice. The solubilized material was injected into mice hearts at the day of birth (80 jg of protein) and subsequently injected intraperitoneally (40 ,ug of protein) each day for 1 month thereafter. Similar regimens have been described by Mitchison (8) and Nossal (9) to induce tolerance to bovine serum albumin and S. adelaide flagellin, respectively, in mice. Although the dose of antigen used in a tolerizing regimen can be critical in determination of the immunological reactivity of the host, we were unable to study the effects of a wide range of antigen doses due to limitations on the quantity of soluble H-2 antigen available. B1O.D2 mice (H-2d) treated with H-2a antigen from the day of birth received skin grafts from congenic B1O.A (H-2a) donors at 1 month of age. The onset of rejection in this group was significantly prolonged (P < 0.001) as compared to that of untreated controls of the same age. However, the mean survival time of [16] [17] [18] (22, 23) have shown an inverse relationship between the strength of cell-mediated immunity and humoral immunity in adult rats treated with multiple injections of cyanogen bromide digests of S. adelaide flagellin or acetoacetylated flagellin. Tolerance of humoral immunity and a heightened cell-mediated immunity to flagellin was observed in' several groups of strain W rats. However, these investigators found a parallel decrease in both cell-mediated and humoral immunity in rats that received multiple injections of antigen from the day of birth. The latter results differ from those reported in the present paper, in that we have observed a dissociation of "humoral" and "cellular" tolerance in mice after neonatal injection of multiple doses of soluble H-2 antigens.
Holman and his colleagues (24, 25) have shown that chronic administration of cell membranes derived from allogeneic liver produces specific "humoral" tolerance in adult mice to spleen cells obtained from the same strain as the liver donors. However, skin allograft reactivity was not altered by the treatment with antigen. A possible explanation of these results is that "cellular immune" tolerance is mediated by "blocking" antibodies, as suggested by the Hellstroms (26, 27) . Induction of humoral tolerance may suppress "blocking" antibodies, as well as cytotoxic, hemagglutinating, and enhancing antibodies. Cell-mediated immunity may remain intact under these conditions, since the humoral antibodies required for continued suppression of cellular immunity are themselves suppressed.
Although the treatment with antigen used in the present study did not elicit "cellular immune" tolerance, changes in the dosage and chemical structure of the soluble H-2 materials may produce a successful tolerizing regimen (24, 25) . These findings have important implications for organ transplantation, since the production of specific immunological tolerance to allogeneic organ grafts remains the ultimate therapeutic challenge with B10 spleen cells.
goal for maintenance of long-term grafts.
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